NVCT Stock Analysis: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$18.44
0.09 (0.49%)
▲
5d:
-6.06%
30d:
+78.86%
90d:
+124.33%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NVCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $18.44, which is considered fair relative to its 30-day fair value range of $10.82 to $22.45.
Technical Outlook: Technically, NVCT is in a uptrend. Immediate support is located at $17.77, while resistance sits at $29.27.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.80 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVCT is in a uptrend. Immediate support is located at $17.77, while resistance sits at $29.27.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.80 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.82 -
$22.45
Company Quality Score
52/100
(HOLD)
Options IV Signal
23th percentile
(COMPLACENCY WARNING)
Volume Confirmation
MODERATE
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 23th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: Trading 72.5% below Wall St target ($31.80)
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$10.82 -
$22.45
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$4.23
(22.9%)
Support & Resistance Levels
Support Level
$17.77
Resistance Level
$29.28
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.63
Wall Street Target
$31.80
(+72.5%)
Share & Embed Analysis
Last updated: July 13, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
